Benign Prostatic Hyperplasia Increases Long-term Chronic Kidney Disease Risk.

IF 6.9 2区医学 Q1 MEDICINE, GENERAL & INTERNAL

Mayo Clinic proceedings Pub Date : 2025-04-08 DOI:10.1016/j.mayocp.2024.11.024

Chenxi Ouyang, Liang Zhou, Jiahao Liu, Long Wang, Yao Lu

{"title":"Benign Prostatic Hyperplasia Increases Long-term Chronic Kidney Disease Risk.","authors":"Chenxi Ouyang, Liang Zhou, Jiahao Liu, Long Wang, Yao Lu","doi":"10.1016/j.mayocp.2024.11.024","DOIUrl":null,"url":null,"abstract":"Objective: To assess the long-term association between benign prostatic hyperplasia (BPH) and chronic kidney disease (CKD) while considering the potential role of BPH medications in any observed associations.Methods: This study used a prospective cohort design. A total of 198,399 male patients without CKD at baseline were recruited from the UK Biobank from 2006 to 2010. Cox proportional hazards models were used to analyze the relationships between BPH, its medication, and the incidence of CKD and end-stage kidney disease (ESKD).Results: After a median follow-up of 13.58 years, 3710 patients with BPH were diagnosed with CKD (hazard ratio [HR], 1.26; 95% CI, 1.10 to 1.45), and 322 patients with BPH were diagnosed with ESKD (HR, 1.49; 95% CI, 0.72 to 3.08), compared with non-BPH patients. Furthermore, BPH medication significantly increased the risk of CKD (HR, 1.48; 95% CI, 1.18 to 1.85) in individuals with BPH compared with those without medication.Conclusion: This study found that people with BPH and those taking BPH medications have a higher long-term risk of CKD. Benign prostatic hyperplasia may contribute to the progression of CKD to ESKD. These findings highlight the importance of monitoring kidney function in patients with BPH.","PeriodicalId":18334,"journal":{"name":"Mayo Clinic proceedings","volume":" ","pages":""},"PeriodicalIF":6.9000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mayo Clinic proceedings","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.mayocp.2024.11.024","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To assess the long-term association between benign prostatic hyperplasia (BPH) and chronic kidney disease (CKD) while considering the potential role of BPH medications in any observed associations.

Methods: This study used a prospective cohort design. A total of 198,399 male patients without CKD at baseline were recruited from the UK Biobank from 2006 to 2010. Cox proportional hazards models were used to analyze the relationships between BPH, its medication, and the incidence of CKD and end-stage kidney disease (ESKD).

Results: After a median follow-up of 13.58 years, 3710 patients with BPH were diagnosed with CKD (hazard ratio [HR], 1.26; 95% CI, 1.10 to 1.45), and 322 patients with BPH were diagnosed with ESKD (HR, 1.49; 95% CI, 0.72 to 3.08), compared with non-BPH patients. Furthermore, BPH medication significantly increased the risk of CKD (HR, 1.48; 95% CI, 1.18 to 1.85) in individuals with BPH compared with those without medication.

Conclusion: This study found that people with BPH and those taking BPH medications have a higher long-term risk of CKD. Benign prostatic hyperplasia may contribute to the progression of CKD to ESKD. These findings highlight the importance of monitoring kidney function in patients with BPH.

查看原文本刊更多论文

良性前列腺增生增加长期慢性肾脏疾病的风险。

目的评估良性前列腺增生症（BPH）与慢性肾脏病（CKD）之间的长期关联，同时考虑良性前列腺增生症药物在任何观察到的关联中的潜在作用：本研究采用前瞻性队列设计。方法：该研究采用前瞻性队列设计，从2006年至2010年从英国生物库中招募了198399名男性患者，他们基线时均未患有慢性肾脏病。研究采用Cox比例危险模型分析良性前列腺增生症、药物治疗与CKD和终末期肾病（ESKD）发病率之间的关系：中位随访13.58年后，与非良性前列腺增生患者相比，3710名良性前列腺增生患者被诊断为CKD（危险比[HR]，1.26；95% CI，1.10至1.45），322名良性前列腺增生患者被诊断为ESKD（HR，1.49；95% CI，0.72至3.08）。此外，与未接受药物治疗的患者相比，良性前列腺增生症患者接受良性前列腺增生症药物治疗会显著增加其罹患慢性肾脏病的风险（HR，1.48；95% CI，1.18 至 1.85）：本研究发现，患有良性前列腺增生症和服用良性前列腺增生症药物的人患慢性肾脏病的长期风险较高。良性前列腺增生可能会导致慢性肾脏病发展为ESKD。这些发现强调了监测良性前列腺增生患者肾功能的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Mayo Clinic proceedings 医学-医学：内科

CiteScore

16.80

自引率

1.10%

发文量

383

审稿时长

37 days

期刊介绍： Mayo Clinic Proceedings is a premier peer-reviewed clinical journal in general medicine. Sponsored by Mayo Clinic, it is one of the most widely read and highly cited scientific publications for physicians. Since 1926, Mayo Clinic Proceedings has continuously published articles that focus on clinical medicine and support the professional and educational needs of its readers. The journal welcomes submissions from authors worldwide and includes Nobel-prize-winning research in its content. With an Impact Factor of 8.9, Mayo Clinic Proceedings is ranked #20 out of 167 journals in the Medicine, General and Internal category, placing it in the top 12% of these journals. It invites manuscripts on clinical and laboratory medicine, health care policy and economics, medical education and ethics, and related topics.